Background and PurposeTo develop an artificial intelligence-based full-process solution for rectal cancer radiotherapy.Materials and MethodsA full-process solution that integrates autosegmentation and automatic treatment planning was developed under a single deep-learning framework. A convolutional neural network (CNN) was used to generate segmentations of the target and the organs at risk (OAR) as well as dose distribution. A script in Pinnacle that simulates the treatment planning process was used to execute plan optimization. A total of 172 rectal cancer patients were used for model training, and 18 patients were used for model validation. Another 40 rectal cancer patients were used for an end-to-end evaluation for both autosegmentation and treatment planning. The PTV and OAR segmentation was compared with manual segmentation. The planning results was evaluated by both objective and subjective assessment.ResultsThe total time for full-process planning without contour modification was 7 min, and an additional 15 min may require for contour modification and re-optimization. The PTV DICE similarity coefficient was greater than 0.85 for all 40 patients in the evaluation dataset while the DICE indices of the OARs also indicated good performance. There were no significant differences between the auto plans and manual plans. The physician accepted 80% of the auto plans without any further operation.ConclusionWe developed a deep learning-based automatic solution for rectal cancer treatment that can improve the efficiency of treatment planning.
Purpose: This study aimed to develop and validate a recurrence prediction of glioma patients through a radiomics feature training and validation model. Patients and methods: In this study, the prediction model was developed in a training cohort that consisted of 88 patients from January 2014 to July 2017 with pathologically confirmed gliomas. Their pre-radiotherapy and recurrence brain magnetic resonance imaging (MRI) images were collected, and the radiomics features were extracted. Clinical factors including age, gender, WHO grade, Isocitrate dehydrogenases (IDH) mutation status and treatment after surgery were collected. The least absolute shrinkage and selection operator (LASSO) regression model was conducted for data dimension reduction, feature selection, and radiomics feature analysis. Internal validation was assessed. An independent validation cohort contained 41 consecutive patients from August 2017 to December 2018. Furthermore, multivariable logistic regression analysis was used to develop the predicting model by combining the radiomics signature and independent clinical factors. Results: In total, 129 patients were included, among which 40 patients had recurrence. The median follow-up time was 27.4 (range, 2.6-79.2) months. We compared the tumor regions radiomics difference between the recurrence and non-recurrence patients. The radiomics signature was associated with the event of recurrence (P < 0.001 for both training and validation cohorts, respectively). The training model showed good discrimination with a C-index of 0.7578 (95%CI: 0.6549-9.8608) through internal validation on T1 contrast-enhanced magnetic resonance imaging, and a consistent trend in calibration. In the validation cohort, the model also showed good discrimination (C-index, 0.6925, 95%CI: 0.5145-0.8705) and good calibration. In the other two sequences of MRI (T1WI, T2WI), the validation model also showed positive results. Meanwhile, radiomics feature and clinical factors were significantly prognostic for recurrence (P value <0.05, respectively). Conclusion:We identified the radiomics feature derived from brain MRI that presented potential in predicting recurrence in glioma patients. This could be beneficial to risk stratification for patients. Further investigation is necessary to include expanded sample size investigation and external multicenter validation.
We try to develop an atlas-guided automatic planning (AGAP) approach and evaluate its feasibility and performance in rectal cancer intensity-modulated radiotherapy. The developed AGAP approach consisted of four independent modules: patient atlas, similar patient retrieval, beam morphing (BM), and plan fine-tuning (PFT) modules. The atlas was setup using anatomy and plan data from Pinnacle auto-planning (P-auto) plans. Given a new patient, the retrieval function searched the top similar patient by a generic Fourier descriptor algorithm and retrieved its plan information. The BM function generated an initial plan for the new patient by morphing the beam aperture from the top similar patient plan. The beam aperture and calculated dose of the initial plan were used to guide the new plan optimization in the PFT function. The AGAP approach was tested on 96 patients by the leave-one-out validation and plan quality was compared with the P-auto plans. The AGAP and P-auto plans had no statistical difference for target coverage and dose homogeneity in terms of V 100% (p = 0.76) and homogeneity index (p = 0.073), respectively. The CI index showed they had a statistically significant difference. But the ΔCI was both 0.02 compared to the perfect CI index of 1. The AGAP approach reduced the bladder mean dose by 152.1 cGy (p < 0.05) and V 50 by 0.9% (p < 0.05), and slightly increased the left and right femoral head mean dose by 70.1 cGy (p < 0.05) and 69.7 cGy (p < 0.05), respectively. This work developed an efficient and automatic approach that could fully automate the IMRT planning process in rectal cancer radiotherapy. It reduced the plan quality dependence on the planner experience and maintained the comparable plan quality with P-auto plans.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.